Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 18Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Astrocytoma 5Oligodendroglioma 4Adenocarcinoma of Lung 4Rectal Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Glioma 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precancerous Conditions 1Pharyngeal Neoplasms 1Paranasal Sinus Neoplasms 1

Interventions

pegfilgrastim 1X-Rays 1Specimen Handling 1Mesenchymal Stem Cell Transplantation 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brenner Tumor × Erlotinib Hydrochloride × Clear all
NCT00217529 2010-09-21

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡